Therapeutic use of Z-521
Phase 3
- Conditions
- primary hypophosphatemic rickets
- Registration Number
- JPRN-jRCT2080221295
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
subjects diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results
Exclusion Criteria
subjects with hyperparathyroidism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum ALP ( alkaline phosphatase ) level<br>serum phosphate level
- Secondary Outcome Measures
Name Time Method